2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | - | - | - | 0 | 0 | 0 | 0 | 732 | 4.442 | 5.274 |
Total Income - EUR | - | - | - | 0 | 6.459 | 5.166 | 5.068 | 5.688 | 9.449 | 19.802 |
Total Expenses - EUR | - | - | - | 28 | 12.769 | 15.372 | 13.376 | 12.016 | 10.103 | 14.772 |
Gross Profit/Loss - EUR | - | - | - | -28 | -6.310 | -10.205 | -8.307 | -6.328 | -653 | 5.030 |
Net Profit/Loss - EUR | - | - | - | -28 | -6.310 | -10.205 | -8.307 | -6.344 | -787 | 4.226 |
Employees | - | - | - | 0 | 2 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Histopathmed S.r.l.
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Check Financial Rating2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 5.244 | 15.442 | 19.908 | 24.976 | 30.317 | 36.184 | 0 | - | - | - |
Current Assets | - | - | - | 44 | 3 | 17 | 29 | 89 | 887 | 6.854 |
Inventories | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Receivables | - | - | - | 0 | 0 | 0 | 0 | 0 | 507 | 307 |
Cash | - | - | - | 44 | 3 | 17 | 29 | 89 | 380 | 6.546 |
Shareholders Funds | - | - | - | 16 | -6.294 | -16.378 | -24.375 | -30.178 | -31.058 | -26.738 |
Social Capital | - | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 |
Debts | - | - | - | 28 | 6.297 | 16.395 | 24.706 | 31.003 | 33.165 | 34.401 |
Income in Advance | - | - | - | 0 | 36.184 | 30.317 | 24.674 | 19.171 | 14.223 | 4.434 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "8622 - 8622" | |||||||||
CAEN Financial Year | 8622 |
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Reports that can be accessed based on the subscription:
Get the contact details for any company and get in touch with it.